Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus CIPRO.
Head-to-head clinical analysis: CINOXACIN versus CIPRO.
CINOXACIN vs CIPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription, leading to bacterial cell death.
1 g orally twice daily for 7-14 days.
Ciprofloxacin 500 mg PO q12h or 400 mg IV q12h for uncomplicated infections; 750 mg PO q12h or 400 mg IV q8h for severe/complicated infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life: 3-5 hours (normal renal function), extended to 8-10 hours in mild-to-moderate renal impairment (CrCl 30-50 mL/min) and up to >10 hours in severe impairment (CrCl <30 mL/min); half-life in elderly may be 5-8 hours due to reduced clearance.
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); biliary/fecal (15-20%, primarily as metabolites); small amount metabolized to 4 metabolites (oxo-, sulfo-, and desethylene-ciprofloxacin).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic